GSK3B and prostate cancer: We now show that blockage of GSK-3β activity leads to a massive reduction in the size of this highly tumorigenic cellular subpopulation of ALDHHIGH prostate cancer cells with a concomitant reduction in clonogenic and migratory potential of human prostate cancer cell lines.